Surfactant therapy for bronchiolitis in critically ill infants

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Jat, Kana R ^a   Chawla, Deepak ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT; PLACEBO;

AIRWAY RESISTANCE; ARTIFICIAL VENTILATION; BRONCHIOLITIS; BRONCHOSPASM; CRITICALLY ILL PATIENT; DRUG EFFICACY; FATTY ACID DESATURATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG COMPLIANCE; LUNG GAS EXCHANGE; OXYGENATION; PNEUMOTHORAX; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; CRITICAL ILLNESS; INFANT; META ANALYSIS; NEWBORN; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; TIME FACTOR;

BRONCHIOLITIS; CHILD, PRESCHOOL; CRITICAL ILLNESS; HUMANS; INFANT; INFANT, NEWBORN; LENGTH OF STAY; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL; TIME FACTORS;

EID: 84991272891     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009194.pub3     Document Type: Review

References (54)

1. Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiologica Scandinavica 1998;42(7):805-10.
2. Luchetti M, Ferrero F, Gallini C, Natale A, Pigna A, Tortorolo L, et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatric Critical Care Medicine 2002;3(3):261-8.
3. Tibby SM, Hatherill M, Wright SM, Wilson P, Postle AD, Murdoch IA. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. American Journal of Respiratory and Critical Care Medicine 2000;162(4 Pt 1):1251-6.
4. Moller JC, Schaible T, Roll C, Schiffmann JH, Bindl L, Schrod L, et al. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study. Intensive Care Medicine 2003;29(3):437-46.
5. Willson DF, Zaritsky A, Bauman LA, Dockery K, James RL, Conrad D, et al. Members of the Mid-Atlantic Pediatric Critical Care Network. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Critical Care Medicine 1999;27(1):188-95.
6. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, DiCarlo JV, Pon S, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005;293(4):470-6.
7. Ardell S, Pfister RH, Soll R. Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD000144.pub2]
8. Barr FE, Pedigo H, Johnson TR, Shepherd VL. Surfactant protein-A enhances uptake of respiratory syncytial virus by monocytes and U937 macrophages. American Journal of Respiratory Cell and Molecular Biology 2000;23(5):586-92.
9. Centers for Disease Control and Prevention. Respiratory Syncytial Virus. www.cdc.gov/rsv/ (accessed 15 February 2011).
10. Dargaville PA, South M, McDougall PN. Surfactant abnormalities in infants with severe viral bronchiolitis. Archives of Disease in Childhood 1996;75(2):133-6.
11. Davison C, Ventre KM, Luchetti M, Randolph AG. Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis. Pediatric Critical Care Medicine 2004;5(5):482-9.
12. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
13. Farley R, Spurling GK, Eriksson L, Del Mar CB. Antibiotics for bronchiolitis in children under two years of age. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD005189.pub4]
14. Fernandes RM, Bialy LM, Vandermeer B, Tjosvold L, Plint AC, Patel H, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD004878.pub4]
15. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD001266.pub4]
16. Goerke J. Pulmonary surfactant: functions and molecular composition. Acta Biochimica et Biophysica 1998;1408(2-3):79-89.
17. McMaster University (developed by Evidence Prime, Inc.). GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. 25th June 2015. Hamilton: McMaster University (developed by Evidence Prime, Inc.), 2015.
18. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. European Respiratory Journal 1999;13(6):1455-76.
19. Handforth J, Friedland JS, Sharland M. Basic epidemiology and immunopathology of RSV in children. Paediatric Respiratory Reviews 2000;1:210-4.
20. Hartling L, Bialy LM, Vandermeer B, Tjosvold L, Johnson DW, Plint AC, et al. Epinephrine for bronchiolitis. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD003123.pub3]
21. Hartling L, Fernandes RM, Bialy L, Milne A, Johnson D, Plint A, et al. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis. BMJ (Clinical Research Ed.) 2011;342:d1714.
22. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatric Infectious Disease Journal 2003;22(6):483-90.
24. Kabir ML, Haq N, Hoque M, Ahmed F, Amin R, Hossain A, et al. Evaluation of hospitalized infants and young children with bronchiolitis -a multi centre study. Mymensingh Medical Journal 2003;12:128-33.
25. Kerr MH, Paton JY. Surfactant protein levels in severe respiratory syncytial virus infection. American Journal of Respiratory and Critical Care Medicine 1999;159(4 Pt 1):1115-8.
26. Lahti M, Lofgren J, Marttila R, Renko M, Klaavuniemi T, Haataja R, et al. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatric Research 2002;51(6):696-9.
27. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
28. Levy BT, Graber MA. Respiratory syncytial virus infection in infants and young children. Journal of Family Practice 1997;45(6):473-81.
29. Liet J-M, Ducruet T, Gupta V, Cambonie G. Heliox inhalation therapy for bronchiolitis in infants. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD006915.pub2]
30. Logan JW, Moya FR. Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials. Therapeutics and Clinical Risk Management 2009;5(1):251-60.
31. Löfgren J, Rämet M, Renko M, Marttila R, Hallman M. Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. Journal of Infectious Diseases 2002;185(3):283-9.
32. Meates-Dennis M. Bronchiolitis. Archives of Disease in Childhood Education and Practice Edition 2005;90:81-6.
33. Meissner HC, Bocchini JA. Reducing RSV hospitalizations AAP modifies recommendations for use of palivizumab in high-risk infants, young children. AAP News 2009;30(7):1.
34. Merkus PJ, de Hoog M, van Gent R, de Jongste JC. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. European Respiratory Journal 2001;18(4):734-7.
35. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ 2009;339:2535.
36. Nasr SZ, Strouse PJ, Soskolne E, Maxvold NJ, Garver KA, Rubin BK, et al. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001;120(1):203-8.
37. Navas L, Wang E, De Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. Journal of Pediatrics 1992;121(3):348-54.
38. Panickar JR, Dodd SR, Smyth RL, Couriel JM. Trends in deaths from respiratory illness in children in England and Wales from 1968 to 2000. Thorax 2005;60:1035-8.
39. Possmayer F. The role of surfactant-associated proteins. American Review of Respiratory Disease 1990;142(4):749-52.
40. Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. Journal of Perinatology 2009;29(Suppl 2):38-43.
41. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
42. Roqué i Figuls M, Giné-Garriga M, Granados Rugeles C, Perrotta C. Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD004873.pub3]
43. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007836]
44. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. Journal of Infectious Diseases 2001;183(1):16-22.
45. Skelton R, Holland P, Darowski M, Chetcuti PA, Morgan LW, Harwood JL. Abnormal surfactant composition and activity in severe bronchiolitis. Acta Paediatrica 1999;88(9):942-6.
46. Soll R. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database of Systematic Reviews 1998, Issue 3. [DOI: 10.1002/14651858.CD001149]
47. Umoren R, Odey F, Meremikwu MM. Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD006435.pub2]
48. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD000181.pub4]
49. Wood AJJ, Jobe AH. Pulmonary surfactant therapy. New England Journal of Medicine 1993;328(12):861-8.
50. Wright JR. Pulmonary surfactant: a front line of lung host defense. Journal of Clinical Investigation 2003;111(10):1453-5.
51. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD006458.pub3]
52. Jat KR, Chawla D. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD009194]
53. Jat KR, Chawla D. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009194.pub2]
54. Ventre K, Haroon M, Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD005150.pub3]